AI-generated analysis. Always verify with the original filing.
Lipocine Inc. reported approximately $19 million in cash and cash equivalents as of January 31, 2026, and announced the last patient last visit in its pivotal Phase 3 clinical trial via press release on February 18, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. As of January 31, 2026, Lipocine Inc. (the “Company”) had approximately $19 million of cash and cash equivalents.
Regulation FD Disclosure. On February 18, 2026, the Company issued a press release announcing last patient last visit (LPLV) in our pivotal Phase 3 clinical tri
Other Events. The information contained above in Item 2.02 is hereby incorporated by reference into this Item 8.01. Item 9.01 Financial Statements and Exhibits.